Advanced Kidney Cancer COE

Advances of Systemic Treatments in Renal Cell Carcinoma - Jens Bedke

Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...

Targeted Therapies with Immunotherapies In Kidney Cancer - Thomas Powles

Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...

Patient Advocacy and Resources in Kidney Cancer - Dena Battle

Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...

Monitoring Treatment Toxicities in Patients with Renal Cell Carcinoma: discussion with Dan George and Tian Zhang

Dan George and Tian Zhang share their views on monitoring treatment toxicities that patients with renal cell carcinoma may experience. Emphasis is placed on counseling patients on expectations and managing baseline comorbities. Maintaining prescribed treatment schedule while focused on quality of life remains the challenging goal for an effective treatment outcome. Biographies: Tian Zhang, MD, Ass...

Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang

(Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...

ASSET, A Pilot Study Using Exercise Physiology in Advanced Renal Cell Carcinoma - Mike Harrison

(Length of Discussion: 12 min) Michael Harrison discusses the ASSET trial with Alicia Morgans. ASSET is a pilot study looking at the drug sunitinib, and its impact on cardiopulmonary function in patients with metastatic kidney cancer. Harrison reviews in detail, the rationale for the study and why the phenomenology of fatigue using exercise physiology may be useful information for clinicians in th...

A Review of Adjuvant Studies in Advanced Renal Cell Carcinoma - Tian Zhang

(Length of Discussion: 18 min) Tian Zhang and Alicia Morgans provide an overview of the trials that are ongoing in the advanced renal cell space. They cover a spectrum from neoadjuvant, to adjuvant, with in-depth highlights on Keynote 564. The relevance in balancing therapy choices with that of toxicities is an important part of the treatment plan for patients as well as a strong consideration in...

CABOSUN Trial Plus an In-depth Discussion of Kidney Cancer Treatments - Toni Choueiri

(Length of Discussion: 22 min) Alicia Morgans and Toni Choueiri engage in a discussion on the treatment options available for mRCC. Toni presents a thorough review of the CABOSUN results, further addressing the process of choosing the right first-line therapy for these patients with intermediate, and poor risk disease. His extensive work in research provides an optimistic vision of having a biomar...

CARMENA: Practice Changing Strategies for Kidney Cancer

(Length of Discussion: 6 min) Charles Ryan and Dan George reflect on the dramatic changes clinicians have seen over the last 12 years in treating kidney cancer. Dan reviews the highlights of the CARMENA trial and the impact that the results have made to treatment strategies for patients, stressing the value of collaborative care and patient selection. Biographies: Daniel George, MD Charles J. Ryan...

Discussion of the IMmotion 151 Trial: Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma - Thomas Keane

(Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.